Clinical Study on Prospective Efficacy of All-Trans Acid, Realgar-Indigo Naturalis Formula Combined with Chemotherapy as Maintenance Treatment of Acute Promyelocytic Leukemia

Table 1

Patients’ characteristics in two groups.

Parameters	Experimental group (𝑛=52)	Control group (𝑛=46)
Gender
Male	32	26
Female	20	20
Age (years)	14–63	13–65
WBC count (×10^9/L)
≤10 × 10^9/L	35	30
>10 × 10^9/L	17	16
Platelet count (×10^9/L)
>40 × 10^9/L	18	16
≤40 × 10^9/L	34	30
Sanz score
Low risk	10	8
Intermediate risk	25	22
High risk	17	16
Median follow-up time (months)	81.5 (20–128)	80 (18–118)

Sanz score: low risk, WBC ≤ 10 × 10⁹/L and platelets > 40 × 10⁹/L; intermediate risk, WBC ≤ 10 × 10⁹/L and platelets ≤ 40 × 10⁹/L; high risk, WBC > 10 × 10⁹/L.
Induction chemotherapy according to Sanz score: low risk, ATRA; intermediate risk, ATRA + DNR/DA; high risk, ATRA + DA + ATO; consolidation chemotherapy, DA/MA/HA regimen used sequentially in all patients despite their Sanz scores.